<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004895</url>
  </required_header>
  <id_info>
    <org_study_id>NU 97X1</org_study_id>
    <secondary_id>NU-97X1</secondary_id>
    <secondary_id>NCI-G00-1685</secondary_id>
    <nct_id>NCT00004895</nct_id>
  </id_info>
  <brief_title>Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery</brief_title>
  <official_title>Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction&#xD;
      that cannot be removed by surgery to live longer and more comfortably.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in&#xD;
      treating patients who have cancer-related bowel obstruction that cannot be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effectiveness of octreotide in the palliation of bowel obstruction&#xD;
           secondary to cancer.&#xD;
&#xD;
        -  Characterize the dose and tolerability of octreotide in this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.&#xD;
&#xD;
      Patients who respond well to study may continue octreotide for palliative effects.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Constipation, Impaction, and Bowel Obstruction</condition>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octreotide acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Inoperable bowel obstruction secondary to cancer OR&#xD;
&#xD;
          -  Metastatic or primary abdominal cancer&#xD;
&#xD;
          -  Patient presents with vomiting&#xD;
&#xD;
          -  Percutaneous gastrostomy tube allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-4&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No documented hypersensitivity to octreotide&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Cameron Muir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>May 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>localized extrahepatic bile duct cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>constipation, impaction, and bowel obstruction</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <keyword>nausea and vomiting</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

